1 Department of Histology and Medical Embryology, University of Rome `La
Sapienza', 00161 Rome, Italy
2 Section of Molecular Medicine, Department of Neuroscience, University of
Siena, I-53100 Siena, Italy
* Author for correspondence (e-mail: marina.bouche{at}uniroma1.it)
Accepted 7 January 2003
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Ryanodine receptors, Myogenic differentiation, Muscle cell populations, Skeletal muscle development
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In mature skeletal muscle fibers, nerve-induced plasma membrane
depolarization activates intracellular responses, which in turn lead to
myofibril contraction. This sequence of events, known as
excitation-contraction coupling, requires dihydropyridine receptor
(DHPR)-mediated activation of the calcium-release channel ryanodine receptor 1
(RyR1). Current models of skeletal muscle excitation-contraction coupling
assume that the DHPR-coupled RyRs are directly controlled by membrane
depolarization, and the uncoupled RyRs indirectly regulated by a
calcium-induced calcium release (CICR) mechanism
(Stern et al., 1997).
There are three RyRs (or calcium relased channels), all encoded by separate
genes (Sutko and Airey, 1996;
Sorrentino and Rizzuto, 2001
).
The skeletal muscle isoform type 1 (RyR1) and the cardiac isoform type 2
(RyR2) are essential for excitation-contraction coupling in skeletal and
cardiac muscle, respectively (Marks et
al., 1989
; Takeshima et al.,
1989
; Nakai et al.,
1990
; Otsu et al.,
1990
; Zorzato et al.,
1990
). The type 3 isoform (RyR3) is expressed in various tissues,
including skeletal muscle (Giannini et
al., 1992
; Giannini et al.,
1995
; Giannini and Sorrentino,
1995
). In mammalian skeletal muscle, the two isoforms RyR1 and
RyR3 are differentially expressed both during late development and in
different muscle types (Conti et al.,
1996
; Bertocchini et al.,
1997
; Tarroni et al.,
1997
). In fact, although RyR1 is expressed in all skeletal muscle
in late developmental stages as well as in the adult, RyR3 is expressed in all
skeletal muscle during late developmental stages and during the first two
weeks after birth, after which it decreases, its expression in the adult being
restricted to a few muscles.
The different roles played by these two receptors can be deduced from the
phenotypes observed in knockout mice. RyR1-knockout mice die at birth from
respiratory failure. In these mice, excitation-contraction coupling is lost,
the muscular mass reduced and maturation of muscle fibers impaired, with signs
of degeneration and central nuclei, all findings that indicate a central role
for RyR1 in these functions (Takeshima et
al., 1994). Lost of the excitation-contraction coupling mechanism
in these mice, even though RyR3 is expressed, suggests that RyR3 is uncoupled
from the voltage sensor and that its activity is dependent on different
mechanisms, probably on a CICR mechanism
(Sorrentino and Reggiani,
1999
). By contrast, RyR3-knockout mice are viable and fertile, and
their muscular mass does not appear to be decreased. However, the amount of
force generated upon electrical stimulation is markedly lower in the skeletal
muscle of a newborn than in that of wild-type mice, which is consistent with
the pattern of expression of RyR3 in fetal and neonatal muscles
(Bertocchini et al., 1997
). In
fact, it has recently been demonstrated that, at least during the peri-natal
period of development, RyR3 plays a role in the amplification of the calcium
signal, probably through a CICR mechanism
(Yang et al., 2001
). In
agreement with this model, double knockout mice
(RyR1//RyR3/) show a more
severe phenotype, both in the impairment of calcium signalling and in the
degeneration of muscle fibers (Ikemoto et
al., 1997
; Barone et al.,
1998
). In fact, the muscular mass in such mice is further reduced,
myofibrils are less organized, the cross-striations are not well aligned and
more muscle fibers show signs of degeneration and central nuclei when compared
with the RyR1-knockout mice. It is unclear, however, whether the main cause of
these defects is improper development or whether it is triggered
degeneration.
The possible role of calcium release from RyRs during mammalian development
has not yet been addressed. In embryonic Xenopus myocytes, calcium
transients, generated by release from intracellular calcium stores, are
essential during development for the construction of the contractile apparatus
and proper somite maturation (Ferrari et
al., 1996; Ferrari et al.,
1998
; Ferrari and Spitzer,
1999
). In the present study we addressed the question of whether,
during mammalian development, calcium release from the sarcoplasmic reticulum
through RyRs is important for the contractile activity of the muscle fibers
alone or whether it may also play a role in the differentiation/developmental
process. To this purpose, we first determined the pattern of expression during
early development of both RyR1 and RyR3 in the different populations of
myogenic cells, and, second, we investigated whether the inhibition of RyRs
activity interferes with the differentiation of muscle cells. We report here,
by immunolocalization and western blot analysis, that RyRs and skeletal myosin
(used as a differentiation parameter) are co-expressed as early as E13 in all
differentiated muscle (e.g. limb, trunk and body wall). Moreover, muscle cells
differentiating in culture, isolated from E9.5 somites (somitic myoblasts),
E11 (embryonic myoblasts) and E16 (fetal myoblasts) limbs and from neonatal
muscle (satellite cells), co-express both receptors upon differentiation.
However, treatment of fetal myoblasts with 100-300 µM ryanodine, which is
known to block channel activity, specifically inhibits myogenic
differentiation, as measured by formation of multinucleated myotubes and
expression of sarcomeric myosin. By contrast, ryanodine does not inhibit
differentiation of embryonic myoblasts or somitic and satellite cells.
Taken together, these results suggest that the activity of RyRs plays a role in the histogenesis of mammalian skeletal muscle and that the inactivation of RyRs in knockout mice may account for the reduction in muscular mass. RyRs probably carry out this role through the inhibition of secondary myogenesis, without affecting primary myogenesis and regeneration.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For western blot analysis, 100 µg of microsomal proteins were loaded on a 5% SDS-PAGE. The gels were blotted onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) and probed with the appropriate specific antisera. Alkaline-phosphatase-conjugated goat anti-mouse IgG (NEN) and alkaline-phosphatase-conjugated goat anti-rabbit IgG (Zymed) were used as secondary antibodies, and detection was performed by means of the CDP-star method (NEN), according to the manufacturer's instructions.
Cell cultures
Somitic cells were prepared from E9.5 somites as previously described
(Vivarelli and Cossu, 1986).
The cells were cultured in Dulbecco's Modified Eagle's Medium (D-MEM, Hyclone)
supplemented with 10% fetal calf serum (FCS, GIBCO) for 3 days. Embryonic and
fetal muscle cells were prepared from E11 and E16 embryo limbs, respectively,
as previously described (Zappelli et al.,
1996
). The cells were grown in D-MEM supplemented with 10% horse
serum, HS (Euroclone, UK) and 3% chick embryo extract (EE) for 3 days. Mouse
satellite cells (MSC) were prepared from 1-2 week post-natal mouse limbs as
previously described (Cossu et al.,
1983
). The cells were grown in D-MEM supplemented with 20% HS and
5% EE. To induce differentiation, the cells were shifted to D-MEM supplemented
with 5% HS and 1.25% EE for 3-5 days.
At the time points indicated, ryanodine (100-300 µM, Sigma) was added to the medium. Cultures were either fixed and processed for immuno- or histo-chemical analysis, or extracted for western blot analysis.
Antisera and antibody
Several different primary polyclonal (pcAb) or monoclonal (mAb) antibodies
were used in this study.
The RyR1- and RyR3-specific pcAb were developed against purified GST fusion
proteins, as previously described
(Giannini and Sorrentino,
1995). Specificity of these antisera was confirmed by western blot
analysis of microsomal fractions from RyR1- or RyR3-HEK293 expressing cells.
The MF20 mAb, which specifically recognizes all sarcomeric myosin heavy chains
(MyHC), was provided by D. A. Fischman (CUMC, NYC, NY)
(Bader et al., 1982
). The F5D
mAb, which recognizes myogenin, was provided by W. E. Wright (SWMC at Dallas,
TX) (Wright et al., 1989
). The
mAb that specifically recognizes
-tubulin was purchased from
Sigma-Aldrich as ascites fluid.
Tissue section preparation and immunofluorescence analysis
Cryosections were prepared from Embedding medium (Jung, Leica Instruments,
Heidelburg) included tissue samples. The sections were rinsed in PBS and
pre-incubated in 1% goat serum in PBS for 30 minutes at room temperature. The
sections were then incubated with the appropriate anti-RyR antiserum (at a
1:100 dilution) together with the anti-myosin heavy-chain mAb MF20 overnight
at 4°C and subsequently washed in PBS containing 1% BSA. Sections were
then incubated with the FITC-conjugated goat anti-mouse (1:200),
TRITC-conjugated goat anti-rabbit (1:200) and Oechst (Sigma-Aldrich, St Louis,
MO). Finally, slides were fixed in 4% paraformaldehyde and mounted in Tris
buffer (pH 9.0) containing 60% glycerol.
Primary cultures were processed for immunofluorescence analysis as described above but were fixed in 4% paraformaldehyde prior to the addition of the primary antibody.
Cultures and slides were photographed under an epi-fluorescence Zeiss microscope.
Intracellular calcium measurements
Cells were loaded with 5 µM Fluo 3-AM (Calbiochem, La Jolla CA) in
Krebs-Ringer-HEPES medium (125 mM NaCl, 5 mM KCl, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2,
6 mM glucose and 25 mM HEPES, adjusted to pH 7.4 with NaOH) for 30 minutes at
room temperature in the dark. The Fluo 3 fluorescence was recorded on an
inverted stage microscope (Nikon) using a 63x objective. Fluo 3 was
excited at 514 nm, images were acquired with a digital CCD camera (Princeton
Instruments, Trenton NY) and calcium signalling was analyzed using computer
software (Metamorph, Universal Imaging Corporation, West Chester, PA).
ß-gal staining
MLC3F-LacZ mice, where the LacZ reporter gene is under
the control of the sarcomeric type 3 fast myosin light chain (MLC3F) promoter
(Kelly et al., 1995), were
provided by M. Buckingham (Pasteur Institute, Paris, France). Primary myogenic
cells were cultured as above, fixed in 4% paraformaldehyde and processed for
ß-gal staining, as previously described
(Kelly et al., 1995
).
RT-PCR reactions
Total RNA was extracted from primary cultures using the Tryzol Reagent
(Invitrogen Life Technologies, Grand Island, NY) according to the
manufacturer's instructions. 100 ng of RNA were reverse-transcribed and
PCR-amplified using the Access RT-PCR system (Promega) according to the
manufacturer's instructions. Reverse transcription was performed in a 50 µl
reaction mixture, at 48°C for 45 minutes. Polymerase was then added to the
reaction; the template was denatured at 94°C for 2 minutes and then
PCR-amplified for 27 cycles, as follows: 30 seconds at 94°C, 1 minute at
60°C (62°C for MyHC and ß-actin), 2 minutes at 68°C; finally,
elongation was performed at 68°C for 7 minutes.
The following forward and reverse primers were used to amplify specific regions of the different RNAs: myf5: forward 5'-GAGCTGCTGAGGGAACAGGTGGAGA-3', reverse 5'-GTTCTTTCGGGACCAGACAGGGCTG-3' (expected band 132 bp); MyoD: forward 5'-CACTACAGTGGCGACTCAGACGCG-3', reverse 5'-CCTGGACTCGCGCACCGCCTCACT-3' (expected band 144 bp); myogenin: forward 5'-CAACCAGGAGGAGCGCGATCTCCG-3', reverse 5'AGGCGCTGTGGGAGTTGCATTCACT-3' (expected band 85 bp); MyHC: forward 5'-AGGGAGCTTGAAAACGAGGT-3', reverse 5'GCTTCCTCCAGCTCGTGCTG-3' (expected band 260 bp); ß-actin: forward 5'-GGTTCCGATGCCCTGAGGCTC-3', reverese 5'-ACTTGCGGTGCAGCATGGAGG-3' (expected band 330 bp). Positive identification of the MyHC RT-PCR product was undertaken by Sau96-I digestion, used as an internal restriction site; positive identification of the myf5, MyoD and myogenin was undertaken by nested PCR using the following oligos, amplifying internal regions of the obtained PCR products: myf5: forward 5'-ACTATTACAGCCTGCCGG-3', reverse 5'-ATGCCGTCAGAGCAGTTG-3'; MyoD: forward 5'-AACTGCTCTGATGGCATG-3', reverse 5'-TCGTAGCCATTCTGCCGC-3'; myogenin: forward 5'-GCTACAGAGGCGGGGGCG-3', reverse 5'-AGTTGCATTCACTGGGCA-3'.
An aliquot of each reaction was then loaded on a TAE-agarose gel containing ethidium bromide, and a digitized image was obtained using a CCD camera Detection System (Diana ll, Raytest).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
To determine whether the expression of RyR1 and RyR3 parallels the onset of skeletal muscle differentiation during early development and whether the two receptors are co-expressed in the same fibers, cryosections of hindlimb and trunk from mouse embryos at different stages of development (E13, 15 and 17) were immunolabelled with specific antisera to RyR1 and RyR3. Muscle fiber differentiation was determined by double immunolabelling using the anti-MyHC antibody MF20. Immunofluorescence analysis demonstrated that both RyR1 and RyR3 are co-expressed in all myosin-positive fibers, in all the stages examined, as early as E13, as well as in all muscle areas (i.e. limb, trunk and body wall). Fig. 2 and Fig. 3 show double immunofluorescence analysis in E13 and E17 limbs. These results demonstrate that the expression of both RyRs parallels muscle fiber differentiation in vivo, in primary (E13) as well as in secondary (E17) fibers, regardless of metabolic and contractile activity. Immunolocalization of the receptors in cryosections from earlier stages of development (E9.5-E11) was not as clear, probably owing to interference in the antigen-antibody reaction due to the different procedure required for sectioning the embryo at that age (data not shown).
|
|
RyR1 and RyR3 are both expressed in primary cultures of all myogenic
cell populations
The expression of RyRs in isolated myogenic cell populations was tested
using primary cell cultures from different stages of development. Somitic,
embryonic, fetal and satellite muscle cells were isolated at different stages
of development and allowed to differentiate in culture. The cells were then
fixed and RyR expression was analyzed by immunofluorescence. The
differentiated status of the cells was determined by double
immuno-fluorescence using the anti-MyHC MF20 antibody. RyR1 and RyR3 were
detected in all cell populations and co-expressed with myosin. Moreover, RyRs
expression was always restricted to myosin-positive cells (Figs
4 and
5).
|
|
Taken together, these data demonstrate that RyR1 and RyR3 are expressed in all myogenic populations (somitic-, embryonic-, fetal- and satellite-cell-derived myotubes) when myogenic differentiation occurs, regardless of the contractile activity of the derived muscle fibers; this demonstrates that during skeletal muscle development, RyRs expression starts long before the maturation of the neuromuscular junctions, which suggests a possible role for these receptors in the control of differentiation and morphogenesis in skeletal muscle in addition to their `canonical' role in excitation-contraction coupling.
To better understand the kinetics of expression of RyRs during muscle cell differentiation, embryonic and fetal myoblasts were plated, and one dish was fixed every 12 hours until differentiation occurred. The cells were then analyzed by double immunofluorescence for the expression of RyRs and myosin. The results are summarized in Fig. 6. In embryonic myoblasts the onset of the expression of both RyRs parallels that of myosin, demonstrating that the expression of the receptors starts at the same time as expression of terminal differentiation markers. By contrast, in fetal myoblasts the expression of both receptors precedes that of myosin by 12-24 hours, thus starting during the initial phase of myogenic differentiation, before the expression of terminal differentiation markers. These results are compatible with a possible role for calcium release from ryanodine receptors during fetal myoblast differentiation.
|
To verify whether the expressed receptors are functionally active, intracellular calcium signalling of fetal and embryonal myoblasts was analyzed by fluorimetric analysis of cytoplasmic calcium concentration on Fluo 3 loaded cells. In order to evaluate the contribution of ryanodine and inositol 1,4,5 trisphosphate [Ins(1,4,5)P3] receptors to calcium signaling in cultured myoblasts, cells were stimulated with the Ins(1,4,5)P3-generating agonist carbachol or with caffeine, a specific agonist of RyRs. Both embryonic and fetal myoblasts responded with a specific calcium rise after stimulation of either Ins(1,4,5)P3 or ryanodine receptors (Fig. 7). To better characterize the organization of intracellular calcium stores in fetal and embryonic myoblasts, we determined whether in these cells Ins(1,4,5)P3 and RyRs are localized on different or common stores. Stimulation with 10 µM carbachol induced a transient increase in the intracellular calcium concentration in both fetal and embryonic myoblasts. A second stimulation with carbachol failed to evoke a significant calcium signal. By contrast, addition of 40 mM caffeine to carbachol-stimulated cells was still able to evoke an increase in the intracellular calcium concentration (Fig. 7a,c). These results suggest that Ins(1,4,5)P3 and ryanodine-sensitive calcium channels regulate independent calcium stores in the cell populations analyzed. Similar results supporting the conclusion that Ins(1,4,5)P3 and ryanodine receptors regulate independent calcium stores were also obtained in experiments where cells were first treated with caffeine and later with carbachol (data not shown). Treatment with 300 µM ryanodine completely abolished caffeine-induced calcium release in both embryonic and fetal myoblasts without affecting the release of calcium from Ins(1,4,5)P3-sensitive channels (Fig. 7b,d).
|
The activity of RyRs is required specifically for fetal myoblast
differentiation
Primary culture systems allowed us to perform functional experiments that
were mainly aimed at inhibiting the receptor activity. To this purpose,
primary cultures of embryonic, fetal and satellite muscle cells were treated
with 100-300 µM ryanodine, an agonist of RyRs, which, at these
concentrations, as expected, blocks calcium release through these channels
(Fig. 7b,d). Cells were treated
with ryanodine for different periods of time: during the proliferative phase
(0-24 hours), during the initial phase of differentiation (24-48 hours) and
after the onset of terminal differentiation (48-72 hours). At the end of the
treatments, the medium was replaced with medium without ryanodine, the cells
were allowed to differentiate before being extracted for protein preparation
and western blot analysis. The expression of skeletal myosin, used as a
differentiative parameter, was analyzed. The results show that treatment of
embryonic myoblasts and satellite cells with ryanodine did not alter the
expression of myosin at any of the treatment times tested
(Fig. 8A). As western blot
analysis could not be performed owing to the limited availability of somitic
cells and the large heterogeneity of primary cultures from E9.5 somites, these
cultures were treated with ryanodine, and differentiation was monitored by
immunofluorescence analysis. Once again, no difference in the number of
myosin-positive cells was detected in ryanodine-treated cells compared with
control cells (data not shown). By contrast, when fetal myoblasts were treated
with ryanodine in culture in the 24-72 hour time range, myosin accumulation
decreased dramatically when compared with control cultures
(Fig. 8A). When fetal myoblasts
were treated with ryanodine during the initial 24 hours in culture
(proliferative phase) and removed and the cells allowed to differentiate, no
effect on the expression of myosin was detectable compared with control cells.
This result may apparently contrast with the known irreversible binding of
ryanodine to the RyR channels. However, although during this first 24 hours in
culture, fetal myoblasts are accumulating RyRs
(Fig. 6), it is conceivable
that, after 24 hours in culture (thus after removal of ryanodine), new RyRs
are continuously synthesized to reach their maximal expression. These new RyR
channels may therefore substitute for the channels that have been blocked by
previous exposure to high levels of ryanodine, and in this way functional RyRs
could be again generated in fetal myoblasts after a ryanodine wash. Addition
of ryanodine to fully differentiated myotubes (after 72 hours) did not alter
the differentiated phenotype (data not shown). To verify whether the
inhibition of terminal differentiation was due to the inhibition of muscle
regulatory factors, the same blots were reacted with the anti-myogenin mAb
F5D; the results indicated that ryanodine treatment did not affect myogenin
expression, even in fetal myoblasts, although myosin expression was inhibited
(Fig. 8A). To verify whether
the expression of other muscle regulatory factors (MRFs) was affected by
ryanodine treatment, total RNA was extracted from fetal myoblasts cultured for
72 hours in the absence of ryanodine or treated with ryanodine in the 24-48
hour time period in culture, and then cultured for the additional 24 hours.
Total RNA was reverse-transcribed and PCR-amplified using primers specific for
MyHC, MyoD, myogenin and myf5; primers specific for ß-actin were used to
normalize the reaction. Specificity of the PCR products was verified either by
digestion using an internal restriction site or by nested PCR using internal
primers, as specified in the Materials and Methods section (data not shown).
The expression of none of the MRFs examined was affected by ryanodine
treatment, whereas, as expected, the expression of myosin was strongly
inhibited (Fig. 8B). Allowing
the PCR reaction to run for further cycles, an amplified product for MyHC was,
as expected, also detectable in ryanodine-treated cells (data not shown).
These results suggest that calcium release from RyRs is required for the
expression of phenotypic differentiation rather than for commitment.
|
To verify whether the inhibition of myosin expression is due to
transcriptional control, fetal myoblasts were prepared from transgenic mice
carrying the nuclear Lac-Z reporter gene driven by the type 3 fast
myosin light chain (MLC3F) promoter (Kelly
et al., 1995; Buckingham et
al., 1998
). Therefore, the transcription of the gene can be easily
identified by in situ ß-galactosidase staining on fixed cells. Fetal
muscle primary cultures from the MLC3F-LacZ mice were treated with
ryanodine during the 24-48 hour or the 48-72 hour time periods in culture. At
the end of the treatment period, the medium was replaced with fresh medium
without ryanodine, and the cells were allowed to differentiate before being
examined for ß-galactosidase staining as well as for the formation of
multinucleated myotubes. Fig. 9
shows that no nuclear ß-galactosidase staining and no formation of
multinucleated myotubes was detectable when the cells were treated during the
24-48 hour time period in culture (Fig.
9C,D) when compared with control cells
(Fig. 9A,B). When the cells
were treated during the 48-72 hour time period in culture, very faint
ß-galactose staining was detectable in thin oligo-nucleated myotubes
(Fig. 9E,F). As expected, no
difference in ß-galactosidase staining or formation of myotubes was
detected in embryonic myoblasts, somitic or satellite cells (data not
shown).
|
Taken together, these results indicate that the activity of RyRs, as inferred from treatment with blocking concentration of ryanodine, is required in fetal myoblasts for terminal differentiation to occur, but not in somitic, embryonic or satellite muscle cells. Moreover, in fetal myoblasts, this activity appears to be required during the initial steps of differentiation (24-48 hours) after withdrawal from the cell cycle, for the transcription of genes typical of terminal differentiation.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The fact that RyR1 and RyR3 are expressed very early during development,
when neuromuscular junctions are not formed yet, suggests that they are
activated through a CICR mechanism. In fact, acetylcholine receptor activity
and maturation of the neuromuscular junction and triad occur in late fetal and
peri-natal developmental stages. Although the main receptor involved in CICR
may be RyR3, the data reported in this paper suggest that RyR1 also acts
through the same mechanism, as has been recently demonstrated in neonatal
muscle (Yang et al.,
2001).
The most important finding in this paper is that calcium release through RyRs appears to be essential for differentiation of fetal myoblasts, the population of muscle cells responsible for the second wave of differentiation during development. In fact, treatment with ryanodine does not impair the expression of skeletal myosin (a differentiation marker) in somitic, embryonic or satellite muscle cells but does significantly inhibit the formation of multinucleated myotubes as well as the expression of skeletal myosin in fetal muscle cells. This inhibition appears to act at the transcriptional level, as demonstrated by the decrease in ß-galactosidase-positive nuclei in fetal myoblasts isolated from transgenic mice carrying Lac-Z driven by the MLC3F promoter. It is noteworthy that, although in embryonic myoblasts the expression of RyR1 and RyR3 appears together with the expression of myosin, in fetal myoblasts it precedes myosin expression by about 12 hours, thus supporting the proposed model for a fetal specific requirement of these receptors for myosin expression. This result may be relevant for the resulting phenotype in the RyR1-knockout and RyR1/RyR3-double knockout mice: in fact, since differentiation of fetal myoblasts, which occurs in secondary myogenesis, is responsible for the building of the bulk of skeletal muscle mass, the reduction in muscular mass in these animal models may be due, at least in part, to the lack of fetal myoblast differentiation.
The experiments reported also indicate that the mechanisms regulating
calcium entry and calcium release can be specific for different myoblast
populations. Different groups have reported that muscle differentiation can be
inhibited by lowering extracellular calcium concentration
(Friday et al., 2000), by
addition of EGTA (Morris and Cole,
1979
), by using inhibitors of L-type calcium channels or by
depleting intracellular calcium stores
(Seigneurin-Venin et al.,
1996
). Calcium transients are required for differentiation and
myofibrillar assembly in embryonic Xenopus myocytes
(Ferrari et al., 1996
;
Ferrari et al., 1998
;
Ferrari and Spitzer, 1999
).
However, the molecular mechanisms through which calcium regulates muscle
differentiation are still unknown. Moreover, the possibility that these
molecular mechanisms may be specific for different myogenic cell populations
has never been addressed.
Many recent reports have focused on the role of calcineurin, a
calcium-dependent phosphatase and its downstream transcription factors NFATs
in skeletal muscle development and differentiation
(Musaro et al., 1999;
Friday et al., 2000
;
Kegley et al., 2001
).
Calcineurin is required for myogenin expression in human satellite cells, as
well as in muscle cell lines, through an NFAT-independent mechanism
(Friday et al., 2000
).
However, our data show that in ryanodine-treated fetal myoblasts, the
expression of myogenin, as well as that of MyoD or myf5, is not inhibited even
though differentiation is impaired. Moreover, cyclosporine, a calcineurin
inhibitor, does not inhibit differentiation of fetal myoblasts (A.P. and M.B.,
unpublished). Taken together, the data reported in this paper suggest that
calcium release from RyR channels is not directly involved in calcineurin
activity, at least in this cell system, and that this mechanism is required
for biochemical differentiation of fetal myoblasts, although not for
commitment. Therefore, multiple calcium-dependent pathways can be activated
during the various phases of myogenesis and during differentiation of
different myogenic populations.
Calcium release represents a general mechanism for the control of
differentiation and development through multiple calcium-dependent pathways
(Berridge et al., 2000). Given
the phenotype of the RyR1-knockout and of the RyR1/RyR3-double-knockout mice,
the data reported here strongly suggest that the reduction of muscular mass
observed in these mice may result from an impairment of secondary (fetal)
myogenesis. Future work will be necessary to better define the mechanisms
responsible for defective skeletal muscle development in these knockout models
and the downstream mechanisms by which the activity of RyRs may regulate these
events.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bader, D., Masaki, T. and Fischman, D. A. (1982). Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol. 95,763 -770.[Abstract]
Barone, V., Bertocchini, F., Bottinelli, R., Protasi, F., Allen, P. D., Franzini, A. C., Reggiani, C. and Sorrentino, V. (1998). Contractile impairment and structural alterations of skeletal muscles from knockout mice lacking type 1 and type 3 ryanodine receptors. FEBS Lett. 422,160 -164.[CrossRef][Medline]
Berridge, M. J., Lipp, P. and Bootman, M. D. (2000). The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1, 11-21.[CrossRef][Medline]
Bertocchini, F., Ovitt, C. E., Conti, A., Barone, V., Scholer,
H. R., Bottinelli, R., Reggiani, C. and Sorrentino, V.
(1997). Requirement for the ryanodine receptor type 3 for
efficient contraction in neonatal skeletal muscles. EMBO
J. 16,6956
-6963.
Buckingham, M., Kelly, R., Tajbakhsh, S. and Zammit, P. (1998). The formation and maturation of skeletal muscle in the mouse: the myosin MLC1F/3F gene as a molecular model. Acta Physiol. Scand. 163,S3 -S5.[Medline]
Conti, A., Gorza, L. and Sorrentino, V. (1996). Differential distribution of ryanodine receptor type 3 (RyR3) gene product in mammalian skeletal muscles. Biochem. J. 316, 19-23.[Medline]
Cossu, G. and Molinaro, M. (1987). Cell heterogeneity in the myogenic lineage. Curr. Top. Dev. Biol. 23,185 -208.[Medline]
Cossu, G., Molinaro, M. and Pacifici, M. (1983). Differential response of satellite cells and embryonic myoblasts to a tumor promoter. Dev. Biol. 98,520 -524.[Medline]
Cossu, G., de Angelis, L., Borello, U., Berarducci, B., Buffa, V., Sonnino, C., Coletta, M., Vivarelli, E., Bouché, M., Lattanzi, L. et al. (2000). Determination, diversification and multipotency of mammalian myogenic cells. Int. J. Dev. Biol. 44,699 -706.[Medline]
Ferrari, M. B. and Spitzer, N. C. (1999). Calcium signaling in the developing Xenopus myotome. Dev. Biol. 213,269 -282.[CrossRef][Medline]
Ferrari, M. B., Rohrbough, J. and Spitzer, N. C. (1996). Spontaneous calcium transients regulate myofibrillogenesis in embryonic Xenopus myocytes. Dev. Biol. 178,484 -497.[CrossRef][Medline]
Ferrari, M. B., Ribbeck, K., Hagler, D. J. and Spitzer, N.
C. (1998). A calcium signaling cascade essential for myosin
thick filament assembly in Xenopus myocytes. J. Cell
Biol. 141,1349
-1356.
Friday, B. B., Horsley, V. and Pavlath, G. K.
(2000). Calcineurin activity is required for the initiation of
skeletal muscle differentiation. J. Cell Biol.
149,657
-666.
Giannini, G. and Sorrentino, V. (1995). Molecular structure and tissue distribution of ryanodine receptors calcium channels. Med. Res. Rev. 15,313 -323.[Medline]
Giannini, G., Clementi, E., Ceci, R., Marziali, G. and Sorrentino, V. (1992). Expression of a ryanodine receptor-Ca2+ channel that is regulated by TGF-beta. Science 257,91 -94.[Medline]
Giannini, G., Conti, A., Mammarella, S., Scrobogna, M. and Sorrentino, V. (1995). The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J. Cell Biol. 128,893 -904.[Abstract]
Hauschka, S. D. (1994). The embryonic origin of skeletal muscle. In Myology, 2nd edn. Vol.1 (ed. A. C. Engel and C. Franzini), pp.3 -72. New York: McGraw-Hill Education.
Ikemoto, T., Komazaki, S., Takeshima, H., Nishi, M., Noda, T., Iino, M. and Endo, M. (1997). Functional and morphological features of skeletal muscle from mutant mice lacking both type 1 and type 3 ryanodine receptors. J. Physiol. 501,305 -312.[Abstract]
Kegley, K. M., Gephart, J., Warren, G. L. and Pavlath, G. K. (2001). Altered primary myogenesis in NFATC3(/) mice leads to decreased muscle size in the adult. Dev. Biol. 232,115 -126.[CrossRef][Medline]
Kelly, R., Alonso, S., Tajbakhsh, S., Cossu, G. and Buckingham, M. (1995). Myosin light chain 3F regulatory sequences confer regionalized cardiac and skeletal muscle expression in transgenic mice. J. Cell Biol. 129,383 -396.[Abstract]
Marks, A. R., Tempst, P., Hwang, K. S., Taubman, M. B., Inui, M., Chadwick, C., Fleischer, S. and Nadal-Ginard, B. (1989). Molecular cloning and characterization of the ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum. Proc. Natl. Acad. Sci. USA 86,8683 -8687.[Abstract]
Morris, G. E. and Cole, R. J. (1979). Calcium and the control of muscle-specific creatine kinase accumulation during skeletal muscle differentiation in vitro. Dev. Biol. 69,146 -158.[Medline]
Musarò, A., McCullagh, K. J., Naya, F. J., Olson, E. N. and Rosenthal, N. (1999). IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400,581 -585.[CrossRef][Medline]
Nakai, J., Imagawa, T., Hakamat, Y., Shigekawa, M., Takeshima, H. and Numa, S. (1990). Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. FEBS Lett. 271,169 -177.[CrossRef][Medline]
Otsu, K., Willard, H. F., Khanna, V. K., Zorzato, F., Green, N.
M. and MacLennan, D. H. (1990). Molecular cloning of cDNA
encoding the Ca2+ release channel (ryanodine receptor) of rabbit
cardiac muscle sarcoplasmic reticulum. J. Biol. Chem.
265,13472
-13483.
Seigneurin-Venin, S., Parrish, E., Marty, I., Rieger, F., Romey, G., Villaz, M. and Garcia, L. (1996). Involvement of the dihydropyridine receptor and internal Ca2+ stores in myoblast fusion. Exp. Cell Res. 223,301 -307.[CrossRef][Medline]
Sorrentino, V. and Reggiani, C. (1999). Expression of the ryanodine receptor type 3 in skeletal muscle. A new partner in excitation-contraction coupling? Trends Cardiovasc. Med. 9,54 -61.[CrossRef][Medline]
Sorrentino, V. and Rizzuto, R. (2001). Molecular genetics of Ca2+ stores and intracellular Ca2+ signalling. Trends Pharmacol. Sci. 22,459 -464.[CrossRef][Medline]
Stern, M. D., Pizarro, G. and Rios, E. (1997).
Local control model of excitation-contraction coupling in skeletal muscle.
J. Gen. Physiol. 110,415
-440.
Stockdale, F. E. (1992). Myogenic cell lineages. Dev. Biol. 154,284 -298.[Medline]
Sutko, J. L. and Airey, J. A. (1996). Ryanodine
receptor Ca2+ release channels: does diversity in form equal
diversity in function? Physiol. Rev.
76,1027
-1071.
Takeshima, H., Iino, M., Takekura, H., Nishi, M., Kuno, J., Minowa, O., Takano, H. and Noda, T. (1994). Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature 369,556 -559.[CrossRef][Medline]
Takeshima, H., Nishimura, S., Matsumoto, T., Ishida, H., Kangawa, K., Minamino, N., Matsuo, H., Ueda, M., Hanaoka, M., Hirose, T. et al. (1989). Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 339,439 -445.[CrossRef][Medline]
Tarroni, P., Rossi, D., Conti, A. and Sorrentino, V.
(1997). Expression of the ryanodine receptor type 3 calcium
release channel during development and differentiation of mammalian skeletal
muscle cells. J. Biol. Chem.
272,19808
-19813.
Vivarelli, E. and Cossu, G. (1986). Neural control of early myogenic differentiation in cultures of mouse somites. Dev. Biol. 117,319 -325.[Medline]
Wright, W. E., Sassoon, D. A. and Lin, V. K. (1989). Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 56,607 -617.[Medline]
Yang, D., Pan, Z., Takeshima, H., Wu, C., Nagaraj, R. Y., Ma, J.
and Cheng, H. (2001). RyR3 amplifies RyR1-mediated
Ca2+-induced Ca2+ release in neonatal mammalian skeletal
muscle. J. Biol. Chem.
276,40210
-40214.
Zappelli, F., Willems, D., Osada, S., Ohno, S., Wetsel, W. C., Molinaro, M., Cossu, G. and Bouché, M. (1996). The inhibition of differentiation caused by TGFbeta in fetal myoblasts is dependent upon selective expression of PKCtheta: a possible molecular basis for myoblast diversification during limb histogenesis. Dev. Biol. 180,156 -164.[CrossRef][Medline]
Zorzato, F., Fujii, J., Otsu, K., Phillips, M., Green, N. M.,
Lai, F. A., Meissner, G. and MacLennan, D. H. (1990).
Molecular cloning of cDNA encoding human and rabbit forms of the
Ca2+ release channel (ryanodine receptor) of skeletal muscle
sarcoplasmic reticulum. J. Biol. Chem.
265,2244
-2256.